| Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability B Mlecnik, G Bindea, HK Angell, P Maby, M Angelova, D Tougeron, ... Immunity 44 (3), 698-711, 2016 | 961 | 2016 |
| The global burden of cancer 2013 Global Burden of Disease Cancer Collaboration JAMA oncology 1 (4), 505, 2015 | 535* | 2015 |
| Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study J Edeline, M Benabdelghani, A Bertaut, J Watelet, P Hammel, JP Joly, ... Journal of Clinical Oncology 37 (8), 658-667, 2019 | 434 | 2019 |
| Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized … P Maby, D Tougeron, M Hamieh, B Mlecnik, H Kora, G Bindea, HK Angell, ... Cancer research 75 (17), 3446-3455, 2015 | 270 | 2015 |
| Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial J Edeline, Y Touchefeu, B Guiu, O Farge, D Tougeron, I Baumgaertner, ... JAMA oncology 6 (1), 51-59, 2020 | 224 | 2020 |
| Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study A Zaanan, L Costes, M Gauthier, D Malka, C Locher, E Mitry, D Tougeron, ... Annals of Oncology 21 (9), 1786-1793, 2010 | 192 | 2010 |
| Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort A Portal, S Pernot, D Tougeron, C Arbaud, AT Bidault, ... British journal of cancer 113 (7), 989-995, 2015 | 184 | 2015 |
| KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 … HH Yoon, D Tougeron, Q Shi, SR Alberts, MR Mahoney, GD Nelson, ... Clinical cancer research 20 (11), 3033-3043, 2014 | 183 | 2014 |
| Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations D Tougeron, E Fauquembergue, A Rouquette, F Le Pessot, R Sesboüé, ... Modern Pathology 22 (9), 1186-1195, 2009 | 181 | 2009 |
| Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study D Tougeron, G Mouillet, I Trouilloud, T Lecomte, R Coriat, T Aparicio, ... Journal of the National Cancer Institute 108 (7), djv438, 2016 | 172 | 2016 |
| Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter … A Adenis, C de la Fouchardiere, B Paule, P Burtin, D Tougeron, J Wallet, ... BMC cancer 16, 1-8, 2016 | 158 | 2016 |
| RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study JB Bachet, O Bouché, J Taieb, O Dubreuil, ML Garcia, A Meurisse, ... Annals of Oncology 29 (5), 1211-1219, 2018 | 156 | 2018 |
| Microsatellite instability: diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer C Evrard, G Tachon, V Randrian, L Karayan-Tapon, D Tougeron Cancers 11 (10), 1567, 2019 | 155 | 2019 |
| Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer D Tougeron, F Di Fiore, S Thureau, N Berbera, I Iwanicki-Caron, ... British journal of cancer 99 (10), 1586-1592, 2008 | 148 | 2008 |
| Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability–high gastric or esophagogastric junction … T André, D Tougeron, G Piessen, C de la Fouchardière, C Louvet, ... Journal of Clinical Oncology 41 (2), 255, 2023 | 143 | 2023 |
| Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide … A Lievre, A Turpin, I Ray-Coquard, K Le Malicot, J Thariat, G Ahle, ... European Journal of Cancer 141, 62-81, 2020 | 143 | 2020 |
| Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer D Tougeron, T Lecomte, JC Pages, C Villalva, C Collin, A Ferru, ... Annals of oncology 24 (5), 1267-1273, 2013 | 123 | 2013 |
| Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro … B Brieau, L Dahan, Y De Rycke, T Boussaha, P Vasseur, D Tougeron, ... Cancer 121 (18), 3290-3297, 2015 | 122 | 2015 |
| Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: are they really heterogeneous? Insights from the FFCD-GTE national cohort T Walter, D Tougeron, E Baudin, K Le Malicot, T Lecomte, D Malka, ... European Journal of Cancer 79, 158-165, 2017 | 112 | 2017 |
| Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer I Iwanicki-Caron, F Di Fiore, I Roque, E Astruc, M Stetiu, A Duclos, ... Journal of clinical oncology 26 (22), 3681-3686, 2008 | 107 | 2008 |
julien Taiebprofessor of medecine Hopital Europeen Georges Pompidou, Université de Paris (Paris-DescartesVerified email at egp.aphp.fr
